Study Compares Outcomes for Treatments of Uncommon Eye Cancer

the ONA take:

Treatment with selumetinib resulted in improved progression-free survival time and tumor response rate compared with chemotherapy, but no improvement was seen in overall survival. Furthermore, the modest improvement in clinical outcomes was accompanied by a high rate of adverse effects. Uveal melanoma arises from melanocytes within the choroid layer of the eye. The study participants were randomly assigned to receive selumetinib (orally twice daily) or chemotherapy (temozolomide, orally daily for 5 of every 28 days, or darcarbazine, IV every 21 days) until disease progression, death, intolerable adverse effects, or withdrawal of consent. Treatment-related adverse events were observed in 97% of patients treated with the drug, and 37% required at least one dose reduction.

Study Compares Outcomes for Treatments of Uncommon Eye Cancer
Study Compares Outcomes for Treatments of Uncommon Eye Cancer
In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall survival, according to a study in the June 18 issue of JAMA. The modest improvement in clinical outcomes was accompanied by a high rate of adverse events.
READ FULL ARTICLE From Newswise
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs